Liver TransplantationNCT07631689
Effect of Discarding Initial Reperfusion Blood on Hemodynamics, Liver Function, and 30-Day Outcomes in Liver Transplantation
A study testing Reperfusion Blood Discard and Standard Liver Transplantation in people with Liver Transplantation and Ischaemia Reperfusion Injury, run by University of Sao Paulo General Hospital.
Trial summary
Hepatic reperfusion during liver transplantation remains a critical phase associated with significant hemodynamic and systemic disturbances, despite advances in surgical and anesthetic management. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Liver Transplantation, Ischaemia Reperfusion Injury, Perioperative Complications
- What is being tested?
- Reperfusion Blood Discard and Standard Liver Transplantation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 132 participants
- Where
- No sites listed yet
- Study dates
- Jul 2026to Feb 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older
- Candidates for liver transplantation at Hospital das Clínicas, University of São Paulo Medical School (HCFMUSP)
- Able to provide written informed consent
Who cannot join
- Inability to provide informed consent
- Previous liver surgery
- Fulminant hepatitis
- Specific liver diseases associated with severe electrolyte disturbances
- End-stage renal disease requiring dialysis
- Combined organ transplantation
Show all 12Show fewer
- Living donor liver transplantation
- Liver retransplantation
- Highly sensitized patients with limited availability of blood products
- Hematologic diseases
- Portal vein thrombosis involving more than 50% of the lumen
- Portopulmonary hypertension (mean pulmonary artery pressure > 20 mmHg), diagnosed preoperatively or intraoperatively
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Assessment of the Impact of Discarding the Initial Reperfusion Blood on Early Liver Function, Cardiovascular and Metabolic Changes and on 30-Day Liver and Renal Outcomes. A Prospective Randomized Trial in Liver Transplantation
Hepatic reperfusion during liver transplantation remains a critical phase associated with significant hemodynamic and systemic disturbances, despite advances in surgical and anesthetic management. This phase is characterized by the release of acidotic, hypothermic, and hyperkalemic blood containing metabolic byproducts and inflammatory mediators resulting from ischemia-reperfusion injury.
Clinically, reperfusion is associated with hemodynamic instability, including reductions in cardiac output and arterial pressure, as well as cardiac dysfunction and arrhythmias, often requiring pharmacologic support. These alterations may affect not only immediate intraoperative stability but also short- and long-term outcomes for both the patient and the graft.
Read more
The abrupt restoration of blood flow to the transplanted liver leads to the systemic release of accumulated metabolites, reactive oxygen species, and inflammatory mediators, contributing to a systemic inflammatory response that may impact distant organs, including the kidneys and heart.
Several revascularization strategies have been investigated to mitigate reperfusion-related injury: initial reperfusion via the portal vein, initial reperfusion through the hepatic artery, and simultaneous reperfusion through the portal vein and hepatic artery.
A less frequently used and insufficiently studied strategy, not routinely or systematically implemented, involves diverting the initial reperfusion blood from the graft to the surgical field, followed by the restoration of hepatic blood outflow to the systemic circulation.
This study hypothesizes that discarding the initial reperfusion blood via the infrahepatic vena cava will attenuate early hemodynamic, metabolic, and inflammatory changes and reduce postoperative complications compared to conventional reperfusion techniques.
Read the detailed description
Hepatic reperfusion during liver transplantation remains a critical phase associated with significant hemodynamic and systemic disturbances, despite advances in surgical and anesthetic management. This phase is characterized by the release of acidotic, hypothermic, and hyperkalemic blood containing metabolic byproducts and inflammatory mediators resulting from ischemia-reperfusion injury.
Clinically, reperfusion is associated with hemodynamic instability, including reductions in cardiac output and arterial pressure, as well as cardiac dysfunction and arrhythmias, often requiring pharmacologic support. These alterations may compromise immediate intraoperative stability and have been associated with adverse short- and long-term outcomes for both the recipient and the graft.
The abrupt restoration of blood flow to the transplanted liver results in the systemic release of accumulated metabolites, reactive oxygen species, and inflammatory mediators, triggering a systemic inflammatory response that may extend beyond the liver and affect distant organs, including the kidneys and heart.
Several revascularization strategies have been investigated to mitigate reperfusion-related injury, including portal vein, hepatic artery, and simultaneous reperfusion approaches. However, none have consistently demonstrated a clear benefit in reducing ischemia-reperfusion injury or improving clinical outcomes. An alternative and less explored strategy involves diverting and discarding the initial reperfusion blood from the graft before restoring venous outflow to the systemic circulation.
Patients listed for liver transplantation at the study center will be systematically screened for eligibility. Written informed consent will be obtained from all eligible participants prior to enrollment, in accordance with institutional ethical standards.
This study is a prospective randomized clinical trial designed to evaluate whether discarding the initial reperfusion blood via the infrahepatic vena cava attenuates early hemodynamic, metabolic, and inflammatory disturbances and improves postoperative outcomes compared with conventional reperfusion techniques.
- Being tested
- Reperfusion Blood Discard, Standard Liver Transplantation
- Keywords
- liver transplantation, ischemia-reperfusion injury, liver graft function, anesthesia, inflamatory response, perioperative complications, hemodynamics
- Medical subject headings
- Reperfusion Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Reperfusion Blood DiscardProcedure or surgery
Discarding of the initial 180 mL of reperfusion blood from the graft via the infrahepatic vena cava during liver transplantation prior to restoration of hepatic venous outflow to systemic circulation.
Standard Liver TransplantationProcedure or surgery
Conventional liver transplantation without discarding the initial reperfusion blood.
| Study group | Role | What they receive |
|---|---|---|
| Reperfusion Blood Discard | Experimental | Liver transplantation with discarding of the initial 180 mL of reperfusion blood via the infrahepatic vena cava prior to restoration of hepatic blood outflow to the systemic circulation Receives: Procedure: Reperfusion Blood Discard |
| Conventional Reperfusion | Active comparator | Standard liver transplantation without discarding the initial reperfusion blood. Receives: Procedure: Standard Liver Transplantation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peak alanine aminotransferase (ALT)
Peak serum ALT level (U/L) as a biomarker of early graft injury following liver transplantation.
Measured: Within 72 hours after transplantation
Secondary outcomes (29)
Arterial Pressure
Monitoring arterial pressure (systolic, diastolic e medium) Unit of Measure: mmHg.
Measured: Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1.
Cardiac Rhythm
Cardiac rhythm monitoring with electrocardiography in ECG lead 2 and V5
Measured: Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1
Cardiac Output
Monitoring continuous cardiac output. Unit of Measure: L/min.
Measured: Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1.
Arterial serum potassium levels
Perioperative changes in arterial potassium levels (Unit of measure: mEq/L).
Measured: Intraoperative and daily from postoperative day 1 up to day 7.
Blood coagulation thromboelastometry
Assessment of intraoperative coagulation changes using rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM parameters, and activated clotting time (ACT).
Measured: Intraoperative (at the start of surgery, 5 minutes after reperfusion, and at the end of surgery).
International normalized ratio (INR)
Assessment of graft function using international normalized ratio (INR).
Measured: Daily up to 72 hours after transplantation.
Aspartate aminotransferase levels (AST)
Assessment of graft injury using serum levels of AST (Unit of measure: U/L).
Measured: Daily up to 7 days and weekly up to 30 days after transplantation.
Serum Tumor Necrosis Factor-alpha (TNF-α)
Serum levels of inflammatory mediator TNF-α (Unit of measure: pg/mL).
Measured: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
Serum B-type natriuretic peptide (BNP)
Assessment of BNP levels as a marker of cardiac hemodynamic stress. Unit of Measure: pg/mL.
Measured: At the start of surgery, 30 minutes after reperfusion and postoperative day 1.
Serum creatinine levels
Assessment of serum creatinine levels to evaluate renal function (Unit of measure: mg/dL),
Measured: Up to 30 days after transplantation.
Postoperative complications
Complications graded according to the Clavien-Dindo classification.
Measured: Within 30 days after transplantation.
ICU length of stay
Days of length of stay in the intensive care unit.
Measured: Up to 30 days after transplantation.
Hospital length of stay
Total hospital length of stay in days.
Measured: Up to 30 days after transplantation.
Arterial serum sodium levels
Perioperative changes in arterial serum sodium levels (Unit of measure: mEq/L).
Measured: Intraoperative and daily from postoperative day 1 up to day 7.
Arterial serum lactate levels
Perioperative changes in arterial serum lactate levels (Unit of measure mg/dL),
Measured: Intraoperative and daily from postoperative day 1 up to day 7.
Arterial serum calcium levels
Perioperative changes in arterial serum calcium levels (Unit of measure mg/dL),
Measured: Intraoperative and daily from postoperative day 1 up to day 7.
Serum glucose levels
Perioperative changes in serum glucose levels (Unit of measure: mg/dL).
Measured: Intraoperative and daily from postoperative day 1 up to day 7.
Arterial serum pH
Perioperative changes in arterial pH units.
Measured: Intraoperative and daily from postoperative day 1 up to day 7.
Arterial serum bicarbonate
Perioperative changes in arterial serum bicarbonate (Unit of measure mmol/L)
Measured: Intraoperative and daily from postoperative day 1 up to day 7.
Factor V activity levels
Assessment of graft function using Factor V activity levels measure as percentage.
Measured: Daily up to 72 hours after transplantation .
Alkaline phosphatase levels
Assessement of graft function using alkaline phosphatase levels (Unit of measure: U/L),
Measured: Daily up to 7 days and weekly up to 30 days after transplantation.
Gamma-glutamyl transferase levels
Assessment of liver function using serum levels of gamma-glutamyl transferase up to 7 days and weekly up to 30 days after transplantation (Unit of measure: U/L).
Measured: Daily up to 7 days and weekly up to 30 days after transplantation.
Serum ammonia levels
Assessment of serum ammonia levels to evaluate liver function.(Unit of measure: mcmol/L).
Measured: Daily up to 7 days and weekly up to 30 days after transplantation.
Serum urea levels
Assessment of serum urea levels to evaluate renal function (Unit of measure: mg/dl),
Measured: Up to 30 days after transplantation.
Urine output
Assessment of renal function measured by daily urine output.
Measured: Up to 30 days after transplantation.
Need for renal replacement therapy
Need for renal replacement therapy (hemodialysis or continuous renal replacement therapy).
Measured: Up to 30 days after transplantation.
Serum Interleukin-6 (IL-6) levels
Serum levels of inflammatory mediator IL-6 (Unit of measure: pg/mL),
Measured: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
Serum Tumor Necrosis Factor-alpha (TNF-α) levels
Serum levels of inflammatory mediator TNF-α levels. (Unit of measure: pg/mL)
Measured: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
Serum Interleukin-17 (IL-17) levels
Serum levels of inflammatory mediator IL-17 (Unit of measure: pg/mL).
Measured: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study startJul 2026 (estimated)
- Primary completionFeb 2028 (estimated)
- Study completionFeb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized in a 1:1 ratio to one of two groups: liver transplantation with discarding of the initial reperfusion blood or conventional liver transplantation without discard. The study follows a parallel-group design to compare the effects of the intervention on early graft function, hemodynamic stability, and postoperative outcomes.
- Masking
- None (open label)
- Enrolment
- 132 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joel Avancini Rocha Filho, University of Sao Paulo General Hospital
- Investigators
- Joel Avancini Rocha Filho, MD, PhD, Principal investigator, Hospital das Clínicas, University of São Paulo Medical SchoolEstela Regina Ramos Figueira, MD, PhD, Study director, Hospital das Clínicas, University of São Paulo Medical SchoolMaria Jose Carvalho Carmona, MD, PhD, Study director, Hospital das Clínicas, University of São Paulo Medical SchoolWellington Andraus, MD, PhD, Study director, Hospital das Clínicas, University of São Paulo Medical SchoolRui Carlos Detsch Junior, MD, Study director, Hospital das Clínicas, University of São Paulo Medical SchoolLuciana Bertocco Paiva Haddad, MD, PhD, Study director, Hospital das Clínicas, University of São Paulo Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07631689
- Sponsor's protocol ID
- 92854125.8.0000.0068
- Other IDs
- 2025/09932-0, 2025
- Status last verified
- Apr 2026
- First submitted
- 15 Apr 2026
- Last updated
- 8 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to institutional and privacy considerations.
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of the Impact of Discarding the Initial Reperfusion Blood on Early Liver Function, Cardiovascular and Metabolic Changes and on 30-Day Liver and Renal Outcomes. A Prospective Randomized Trial in Liver Transplantation
- ClinicalTrials.gov ID
- NCT07631689
- Acronym / sponsor ID
- 92854125.8.0000.0068
- Keywords
- liver transplantation, ischemia-reperfusion injury, liver graft function, anesthesia, inflamatory response, perioperative complications, hemodynamics
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 132 participants (estimated)
- Lead sponsor
- University of Sao Paulo General HospitalUniversity, hospital or other
- Study start
- Jul 2026 (estimated)
- Primary completion
- Feb 2028 (estimated)
- Study completion
- Feb 2028 (estimated)
- First posted
- 8 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hepatic reperfusion during liver transplantation remains a critical phase associated with significant hemodynamic and systemic disturbances, despite advances in surgical and anesthetic management. This phase is characterized by the release of acidotic, hypothermic, and hyperkalemic blood containing metabolic byproducts and inflammatory mediators resulting from ischemia-reperfusion injury.
Clinically, reperfusion is associated with hemodynamic instability, including reductions in cardiac output and arterial pressure, as well as cardiac dysfunction and arrhythmias, often requiring pharmacologic support. These alterations may affect not only immediate intraoperative stability but also short- and long-term outcomes for both the patient and the graft.
The abrupt restoration of blood flow to the transplanted liver leads to the systemic release of accumulated metabolites, reactive oxygen species, and inflammatory mediators, contributing to a systemic inflammatory response that may impact distant organs, including the kidneys and heart.
Several revascularization strategies have been investigated to mitigate reperfusion-related injury: initial reperfusion via the portal vein, initial reperfusion through the hepatic artery, and simultaneous reperfusion through the portal vein and hepatic artery.
A less frequently used and insufficiently studied strategy, not routinely or systematically implemented, involves diverting the initial reperfusion blood from the graft to the surgical field, followed by the restoration of hepatic blood outflow to the systemic circulation.
This study hypothesizes that discarding the initial reperfusion blood via the infrahepatic vena cava will attenuate early hemodynamic, metabolic, and inflammatory changes and reduce postoperative complications compared to conventional reperfusion techniques.
Detailed description
Hepatic reperfusion during liver transplantation remains a critical phase associated with significant hemodynamic and systemic disturbances, despite advances in surgical and anesthetic management. This phase is characterized by the release of acidotic, hypothermic, and hyperkalemic blood containing metabolic byproducts and inflammatory mediators resulting from ischemia-reperfusion injury.
Clinically, reperfusion is associated with hemodynamic instability, including reductions in cardiac output and arterial pressure, as well as cardiac dysfunction and arrhythmias, often requiring pharmacologic support. These alterations may compromise immediate intraoperative stability and have been associated with adverse short- and long-term outcomes for both the recipient and the graft.
The abrupt restoration of blood flow to the transplanted liver results in the systemic release of accumulated metabolites, reactive oxygen species, and inflammatory mediators, triggering a systemic inflammatory response that may extend beyond the liver and affect distant organs, including the kidneys and heart.
Several revascularization strategies have been investigated to mitigate reperfusion-related injury, including portal vein, hepatic artery, and simultaneous reperfusion approaches. However, none have consistently demonstrated a clear benefit in reducing ischemia-reperfusion injury or improving clinical outcomes. An alternative and less explored strategy involves diverting and discarding the initial reperfusion blood from the graft before restoring venous outflow to the systemic circulation.
Patients listed for liver transplantation at the study center will be systematically screened for eligibility. Written informed consent will be obtained from all eligible participants prior to enrollment, in accordance with institutional ethical standards.
This study is a prospective randomized clinical trial designed to evaluate whether discarding the initial reperfusion blood via the infrahepatic vena cava attenuates early hemodynamic, metabolic, and inflammatory disturbances and improves postoperative outcomes compared with conventional reperfusion techniques.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants will be randomized in a 1:1 ratio to one of two groups: liver transplantation with discarding of the initial reperfusion blood or conventional liver transplantation without discard. The study follows a parallel-group design to compare the effects of the intervention on early graft function, hemodynamic stability, and postoperative outcomes.
| Arm | Type | Receives |
|---|---|---|
| Reperfusion Blood Discard | Experimental | Procedure: Reperfusion Blood DiscardLiver transplantation with discarding of the initial 180 mL of reperfusion blood via the infrahepatic vena cava prior to restoration of hepatic blood outflow to the systemic circulation |
| Conventional Reperfusion | Active comparator | Procedure: Standard Liver TransplantationStandard liver transplantation without discarding the initial reperfusion blood. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 18 years or older
- Candidates for liver transplantation at Hospital das Clínicas, University of São Paulo Medical School (HCFMUSP)
- Able to provide written informed consent
Key exclusion criteria (12 listed)
- Inability to provide informed consent
- Previous liver surgery
- Fulminant hepatitis
- Specific liver diseases associated with severe electrolyte disturbances
- End-stage renal disease requiring dialysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Reperfusion Blood DiscardDiscarding of the initial 180 mL of reperfusion blood from the graft via the infrahepatic vena cava during liver transplantation prior to restoration of hepatic venous outflow to systemic circulation. | Procedure or surgery | Reperfusion Blood Discard |
| Standard Liver TransplantationConventional liver transplantation without discarding the initial reperfusion blood. | Procedure or surgery | Conventional Reperfusion |
Primary outcome
Peak alanine aminotransferase (ALT)
Time frame: Within 72 hours after transplantation
Peak serum ALT level (U/L) as a biomarker of early graft injury following liver transplantation.
29 secondary outcomes
Arterial Pressure
Time frame: Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1.
Cardiac Rhythm
Time frame: Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1
Cardiac Output
Time frame: Intraoperative, during reperfussion, 30 minutes after reperfusion, and postoperative day 1.
Arterial serum potassium levels
Time frame: Intraoperative and daily from postoperative day 1 up to day 7.
Blood coagulation thromboelastometry
Time frame: Intraoperative (at the start of surgery, 5 minutes after reperfusion, and at the end of surgery).
International normalized ratio (INR)
Time frame: Daily up to 72 hours after transplantation.
Aspartate aminotransferase levels (AST)
Time frame: Daily up to 7 days and weekly up to 30 days after transplantation.
Serum Tumor Necrosis Factor-alpha (TNF-α)
Time frame: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
Serum B-type natriuretic peptide (BNP)
Time frame: At the start of surgery, 30 minutes after reperfusion and postoperative day 1.
Serum creatinine levels
Time frame: Up to 30 days after transplantation.
Postoperative complications
Time frame: Within 30 days after transplantation.
ICU length of stay
Time frame: Up to 30 days after transplantation.
Hospital length of stay
Time frame: Up to 30 days after transplantation.
Arterial serum sodium levels
Time frame: Intraoperative and daily from postoperative day 1 up to day 7.
Arterial serum lactate levels
Time frame: Intraoperative and daily from postoperative day 1 up to day 7.
Arterial serum calcium levels
Time frame: Intraoperative and daily from postoperative day 1 up to day 7.
Serum glucose levels
Time frame: Intraoperative and daily from postoperative day 1 up to day 7.
Arterial serum pH
Time frame: Intraoperative and daily from postoperative day 1 up to day 7.
Arterial serum bicarbonate
Time frame: Intraoperative and daily from postoperative day 1 up to day 7.
Factor V activity levels
Time frame: Daily up to 72 hours after transplantation .
Alkaline phosphatase levels
Time frame: Daily up to 7 days and weekly up to 30 days after transplantation.
Gamma-glutamyl transferase levels
Time frame: Daily up to 7 days and weekly up to 30 days after transplantation.
Serum ammonia levels
Time frame: Daily up to 7 days and weekly up to 30 days after transplantation.
Serum urea levels
Time frame: Up to 30 days after transplantation.
Urine output
Time frame: Up to 30 days after transplantation.
Need for renal replacement therapy
Time frame: Up to 30 days after transplantation.
Serum Interleukin-6 (IL-6) levels
Time frame: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
Serum Tumor Necrosis Factor-alpha (TNF-α) levels
Time frame: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
Serum Interleukin-17 (IL-17) levels
Time frame: At the start of surgery, end of surgery, postoperative day 1, and postoperative day 3.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to institutional and privacy considerations.
Related trials for Liver Transplantation
Active, not recruiting
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
Transplant;Failure,Kidney, Transplant; Failure, Liver
Recruiting
In-situ vs Ex-situ Liver Preservation
Liver Disease (Alcoholic or Not), Transplantation
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Recruiting
Avoiding Recooling After Normothermic Machine Perfusion in Liver Transplantation
Liver Transplantation (LT), Ischemia-Reperfusion Injury
Recruiting
Peer Support for Liver Transplant Recipients With History of ALD
Alcohol Use Disorder, Alcohol Related Liver Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joel Avancini Rocha Filho, MD, PhD principal investigator
Hospital das Clínicas, University of São Paulo Medical School
Estela Regina Ramos Figueira, MD, PhD study director
Hospital das Clínicas, University of São Paulo Medical School
Maria Jose Carvalho Carmona, MD, PhD study director
Hospital das Clínicas, University of São Paulo Medical School
Questions about this trial
What is this clinical trial studying?
A study testing Reperfusion Blood Discard and Standard Liver Transplantation in people with Liver Transplantation and Ischaemia Reperfusion Injury, run by University of Sao Paulo General Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joel Avancini Rocha Filho, MD, PhD (+55 11 981422500, joel.rocha@hc.fm.usp.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peak alanine aminotransferase (ALT) (time frame: Within 72 hours after transplantation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026.